HIV-1 Diversity, Drug-Resistant Mutations, and Viral Evolution among High-Risk Individuals in Phase II HIV Vaccine Trial Sites in Southern China

Haiyan Qi; Ke Zhao; Fei Xu; Xuzhao Zhang; Zhiyong Zhang; Li Yang; Chunling Li; Xu Liang; Weigui Guo; Shihai Chen; Zhihao Liu; Wenyan Zhang; Xiao-Fang Yu

doi:10.1371/journal.pone.0068656

Loading metrics

Open Access

Peer-reviewed

Research Article

HIV-1 Diversity, Drug-Resistant Mutations, and Viral Evolution among High-Risk Individuals in Phase II HIV Vaccine Trial Sites in Southern China

Haiyan Qi,

Affiliation Cancer Institute, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
⨯
Ke Zhao,

Affiliation Institute of Virology and AIDS Research, First Hospital of Jilin University, Changchun, Jilin, China
⨯
Fei Xu,

Affiliation Cancer Institute, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
⨯
Xuzhao Zhang,

Affiliation Cancer Institute, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
⨯
Zhiyong Zhang,

Affiliation School of Public Health, Guangxi Medical University, Nanning, Guangxi, China
⨯
Li Yang,

Affiliation School of Public Health, Guangxi Medical University, Nanning, Guangxi, China
⨯
Chunling Li,

Affiliation School of Public Health, Guangxi Medical University, Nanning, Guangxi, China
⨯
Xu Liang,

Affiliation Centers for Disease Control and Prevention, Baise, Guangxi, China
⨯
Weigui Guo,

Affiliation Centers for Disease Control and Prevention, Beihai, Guangxi, China
⨯
Shihai Chen,

Affiliation Centers for Disease Control and Prevention, Nanning, Guangxi, China
⨯
Zhihao Liu,

Affiliation Centers for Disease Control and Prevention, Baise, Guangxi, China
⨯
Wenyan Zhang,

Affiliation Institute of Virology and AIDS Research, First Hospital of Jilin University, Changchun, Jilin, China
⨯
Xiao-Fang Yu

* E-mail: xfyu@jhpsh.edu

Affiliations Cancer Institute, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, Institute of Virology and AIDS Research, First Hospital of Jilin University, Changchun, Jilin, China, Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America
⨯

HIV-1 Diversity, Drug-Resistant Mutations, and Viral Evolution among High-Risk Individuals in Phase II HIV Vaccine Trial Sites in Southern China

Haiyan Qi,
Ke Zhao,
Fei Xu,
Xuzhao Zhang,
Zhiyong Zhang,
Li Yang,
Chunling Li,
Xu Liang,
Weigui Guo,
Shihai Chen

Published: July 15, 2013
https://doi.org/10.1371/journal.pone.0068656

Reader Comments (0)

Post a new comment on this article

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

HIV-1
Is the Subject Area "HIV-1" applicable to this article?

Thanks for your feedback.
Cities
Is the Subject Area "Cities" applicable to this article?

Thanks for your feedback.
Phylogenetic analysis
Is the Subject Area "Phylogenetic analysis" applicable to this article?

Thanks for your feedback.
Mutation detection
Is the Subject Area "Mutation detection" applicable to this article?

Thanks for your feedback.
HIV vaccines
Is the Subject Area "HIV vaccines" applicable to this article?

Thanks for your feedback.
Antivirals
Is the Subject Area "Antivirals" applicable to this article?

Thanks for your feedback.
HIV epidemiology
Is the Subject Area "HIV epidemiology" applicable to this article?

Thanks for your feedback.
Protease inhibitor therapy
Is the Subject Area "Protease inhibitor therapy" applicable to this article?

Thanks for your feedback.